95 related articles for article (PubMed ID: 11753972)
21. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
22. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
Nakanishi K; Kawai T; Torikata C; Aurues T; Ikeda T
Cancer; 1998 Feb; 82(4):724-32. PubMed ID: 9477106
[TBL] [Abstract][Full Text] [Related]
23. Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse.
Meijer-van Gelder ME; Look MP; Bolt-de Vries J; Peters HA; Klijn JG; Foekens JA
J Clin Oncol; 1999 May; 17(5):1449-57. PubMed ID: 10334530
[TBL] [Abstract][Full Text] [Related]
24. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
25. Immunohistologic evaluation of invasion-associated proteases in breast carcinoma.
Visscher DW; Sarkar F; LoRusso P; Sakr W; Ottosen S; Wykes S; Crissman JD
Mod Pathol; 1993 May; 6(3):302-6. PubMed ID: 8346178
[TBL] [Abstract][Full Text] [Related]
26. Stromelysin-3 expression by mammary tumor-associated fibroblasts under in vitro breast cancer cell induction.
Wang CS; Têtu B
Int J Cancer; 2002 Jun; 99(6):792-9. PubMed ID: 12115479
[TBL] [Abstract][Full Text] [Related]
27. Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
Ruppert C; Ehrenforth S; Scharrer I; Halberstadt E
Cancer Detect Prev; 1997; 21(5):452-9. PubMed ID: 9307848
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
[TBL] [Abstract][Full Text] [Related]
29. Melanocyte mediated paracrine induction of extracellular matrix degrading proteases in squamous cell carcinoma cells.
Borchers AH; Sanders LA; Powell MB; Bowden GT
Exp Cell Res; 1997 Feb; 231(1):61-5. PubMed ID: 9056412
[TBL] [Abstract][Full Text] [Related]
30. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
31. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis.
Têtu B; Brisson J; Wang CS; Lapointe H; Beaudry G; Blanchette C; Trudel D
Breast Cancer Res; 2006; 8(3):R28. PubMed ID: 16776850
[TBL] [Abstract][Full Text] [Related]
32. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
33. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
34. Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression.
Ahmad A; Hanby A; Dublin E; Poulsom R; Smith P; Barnes D; Rubens R; Anglard P; Hart I
Am J Pathol; 1998 Mar; 152(3):721-8. PubMed ID: 9502414
[TBL] [Abstract][Full Text] [Related]
35. Multiparametric prognostic evaluation of biological factors in primary breast cancer.
Spyratos F; Martin PM; Hacène K; Romain S; Andrieu C; Ferrero-Poüs M; Deytieux S; Le Doussal V; Tubiana-Hulin M; Brunet M
J Natl Cancer Inst; 1992 Aug; 84(16):1266-72. PubMed ID: 1640487
[TBL] [Abstract][Full Text] [Related]
36. Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry.
Kennedy S; Duffy MJ; Duggan C; Barnes C; Rafferty R; Kramer MD
Br J Cancer; 1998 May; 77(10):1638-41. PubMed ID: 9635840
[TBL] [Abstract][Full Text] [Related]
37. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.
Heiss MM; Allgayer H; Gruetzner KU; Babic R; Jauch KW; Schildberg FW
Ann Surg; 1997 Dec; 226(6):736-44; discussion 744-5. PubMed ID: 9409572
[TBL] [Abstract][Full Text] [Related]
38. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
39. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma.
Okusa Y; Ichikura T; Mochizuki H
Cancer; 1999 Mar; 85(5):1033-8. PubMed ID: 10091785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
